Topical immunomodulators for management of oral mucosal conditions, a systematic review; part I: Calcineurin inhibitors

Expert Opinion on Emerging Drugs

Volumn 15, Issue 4, 2010, Pages 713-726

  Elad, Sharon ^a   Epstein, Joel B ^b   Yarom, Noam ^c,d   Drucker, Scott ^e   Tzach, Rinat ^a   Von Bltzingslöwen, Inger ^f  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF ILLINOIS   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

calcineurin inhibitors; cyclosporine; evidence based; mechanism; mucosal; oral; pimecrolimus; tacrolimus; topical

Indexed keywords

CALCINEURIN INHIBITOR; CLOBETASOL; CLOBETASOL PROPIONATE; CURCUMIN; CYCLOSPORIN; CYCLOSPORIN A; EN 3285; ETANERCEPT; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOMODULATING AGENT; MANUKA HONEY; MORPHINE; PIMECROLIMUS; RAPAMYCIN; RECOMBINANT EPIDERMAL GROWTH FACTOR; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

BREAST TENDERNESS; BURNING SENSATION; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG RESEARCH; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; LICHEN PLANUS; LIP DISEASE; ORAL MUCOSAL DISEASE; PETECHIA; PRURITUS; REVIEW; SYSTEMATIC REVIEW; TOPICAL TREATMENT; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ANIMALS; CALCINEURIN; CYCLOSPORINE; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOUTH DISEASES; MOUTH MUCOSA; TACROLIMUS;

EID: 78649456532     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.528389     Document Type: Review

References (93)

1. Gonzalez-Moles MA, Scully C. Vesiculo-erosive oral mucosal disease - management with topical corticosteroids: (2) protocols, monitoring of effects and adverse reactions, and the future. J Dent Res 2005;84:302-8 (Pubitemid 43822009)
2. Gonzalez-Moles MA, Scully C. Vesiculo-erosive oral mucosal disease - management with topical corticosteroids: (1) fundamental principles and specific agents available. J Dent Res 2005;84:294-301 (Pubitemid 43822008)
3. Oxford Center for Evidence-Based Medicine - Levels of Evidence; 2009. Available from: http://www.cebm. net/index.aspx?o=1025 [Accessed 3 January 2010]
4. Meier J. Oral cGVHD; 2010
5. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38
6. Thongprasom K, Chaimusig M, Korkij W, et al. A randomized-controlled trial to compare topical cyclosporin with triamcinolone acetonide for the treatment of oral lichen planus. J Oral Pathol Med 2007;36:142-6
7. Yoke PC, Tin GB, Kim MJ, et al. A randomized controlled trial to compare steroid with cyclosporine for the topical treatment of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:47-55
8. Conrotto D, Carbone M, Carrozzo M, et al. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial. Br J Dermatol 2006;154:139-45
9. Sieg P, Von Domarus H, Von Zitzewitz V, et al. Topical cyclosporin in oral lichen planus: a controlled, randomized, prospective trial. Br J Dermatol 1995;132:790-4
10. Epstein JB, Truelove EL. Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:532-6
11. Epstein JB, Reece DE. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 1994;13:81-6
12. Eisen D, Ellis CN, Duell EA, et al. Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis. N Engl J Med 1990;323:290-4
13. Femiano F, Gombos F, Scully C. Oral erosive/ulcerative lichen planus: preliminary findings in an open trial of sulodexide compared with cyclosporine (ciclosporin) therapy. Int J Dermatol 2003;42:308-11
14. Itin P, Surber C, Buchner S. Lack of effect after local treatment with a new ciclosporin formulation in recalcitrant erosive oral lichen planus. Dermatology 1992;185:262-5
15. Harpenau LA, Plemons JM, Rees TD. Effectiveness of a low dose of cyclosporine in the management of patients with oral erosive lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:161-7
16. Levell NJ, MacLeod RI, Marks JM. Lack of effect of cyclosporin mouthwash in oral lichen planus. Lancet 1991;337:796-7
17. Becherel PA, Chosidow O, Boisnic S, et al. Topical cyclosporine in the treatment of oral and vulvar erosive lichen planus: a blood level monitoring study. Arch Dermatol 1995;131:495-6
18. Ho VC, Gupta AK, Ellis CN, et al. Treatment of severe lichen planus with cyclosporine. J Am Acad Dermatol 1990;22:64-8
19. Eisen D, Ellis CN. Topical cyclosporine for oral mucosal disorders. J Am Acad Dermatol 1990;23:1263-4; discussion 1263-1254
20. Ho VC, Conklin RJ. Effect of topical cyclosporine rinse on oral lichen planus. N Engl J Med 1991;325:435
21. Jungell P, Malmstrom M. Cyclosporin A mouthwash in the treatment of oral lichen planus. Int J Oral Maxillofac Surg 1996;25:60-2
22. Voute AB, Schulten EA, Langendijk PN, et al. Cyclosporin A in an adhesive base for treatment of recalcitrant oral lichen planus. An open trial. Oral Surg Oral Med Oral Pathol 1994;78:437-41
23. Porter SR, Scully C, Eveson JW. The efficacy of topical cyclosporin in the management of desquamative gingivitis due to lichen planus. Br J Dermatol 1993;129:753-5
24. Demitsu T, Sato T, Inoue T, et al. Corticosteroid-resistant erosive oral lichen planus successfully treated with topical cyclosporine therapy. Int J Dermatol 2000;39:79-80
25. Petruzzi M, De Benedittis M, Pastore L, et al. Peno-gingival lichen planus. J Periodontol 2005;76:2293-8
26. Gaeta GM, Serpico R, Femiano F, et al. Cyclosporin bioadhesive gel in the topical treatment of erosive oral lichen planus. Int J Immunopathol Pharmacol 1994;7:125-32
27. Gooptu C, Staughton RC. Use of topical cyclosporin in oral pemphigus. J Am Acad Dermatol 1998;38:860-1
28. Eisen D, Ellis CN, Voorhees JJ. Topical cyclosporine for oral bullous disorders. J Am Acad Dermatol 1990;23:936-7
29. Heinemann C, Fischer T, Barta U, et al. Plasma cell mucositis with oral and genital involvement - successful treatment with topical cyclosporin. J Eur Acad Dermatol Venereol 2006;20:739-40
30. Al Johani KA, Hegarty AM, Porter SR, et al. Calcineurin inhibitors in oral medicine. J Am Acad Dermatol 2009;61:829-40
31. Carrozzo M, Gandolfo S. The management of oral lichen planus. Oral Dis 1999;5:196-205
32. Eisen D. The therapy of oral lichen planus. Crit Rev Oral Biol Med 1993;4:141-58
33. Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:164-78 (Pubitemid 41020782)
34. van Rossum HH, de Fijter JW, van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit 2010;32:3-10
35. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994;344:883
36. Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:187-93
37. Laeijendecker R, Tank B, Dekker SK, et al. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 2006;86:227-9
38. Lozada-Nur FI, Sroussi HY. Tacrolimus powder in Orabase 0.1% for the treatment of oral lichen planus and oral lichenoid lesions: an open clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:744-9
39. Byrd JA, Davis MD, Bruce AJ, et al. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol 2004;140:1508-12
40. Thomson MA, Hamburger J, Stewart DG, et al. Treatment of erosive oral lichen planus with topical tacrolimus. J Dermatolog Treat 2004;15:308-14
41. Hodgson TA, Sahni N, Kaliakatsou F, et al. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol 2003;13:466-70
42. Olivier V, Lacour JP, Mousnier A, et al. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol 2002;138:1335-8
43. Morrison L, Kratochvil III FJ, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002;47:617-20
44. Kaliakatsou F, Hodgson TA, Lewsey JD, et al. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002;46:35-41
45. Rozycki TW, Rogers III RS, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002;46:27-34
46. Rabanal A, Bral M, Goldstein G. Management of a patient with severe erosive lichen planus in need of an immediate complete denture: a clinical report. J Prosthet Dent 2007;97:252-5
47. Riano Arguelles A, Martino Gorbea R, Iglesias Zamora ME, et al. Topic tacrolimus, alternative treatment for oral erosive lichen planus resistant to steroids: a case report. Med Oral Patol Oral Cir Bucal 2006;11: E462-6
48. Shichinohe R, Shibaki A, Nishie W, et al. Successful treatment of severe recalcitrant erosive oral lichen planus with topical tacrolimus. J Eur Acad Dermatol Venereol 2006;20:66-8
49. Donovan JC, Hayes RC, Burgess K, et al. Refractory erosive oral lichen planus associated with hepatitis C: response to topical tacrolimus ointment. J Cutan Med Surg 2005;9:43-6
50. Fricain JC, Sibaud V, Campana F, et al. Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus. Dermatology 2005;210:229-32
51. Shen JT, Pedvis-Leftick A. Mucosal staining after using topical tacrolimus to treat erosive oral lichen planus. J Am Acad Dermatol 2004;50:326
52. Lener EV, Brieva J, Schachter M, et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 2001;137:419-22
53. Corrocher G, Di Lorenzo G, Martinelli N, et al. Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. J Clin Periodontol 2008;35:244-9
54. Tavassol F, Starke OF, Volker B, et al. Heat-shock protein expression and topical treatment with tacrolimus in oral lichen planus: an immunohistochemical study. Int J Oral Maxillofac Surg 2008;37:66-9
55. Vente C, Reich K, Rupprecht R, et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999;140:338-42
56. Chaudhry SI, Pabari S, Hodgson TA, et al. The use of topical calcineurin inhibitors in the management of oral lichen planus. J Eur Acad Dermatol Venereol 2007;21:554-6
57. Becker JC, Houben R, Vetter CS, et al. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 2006;6:7
58. Mattsson U, Magnusson B, Jontell M. Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110: e19-25
59. Schlaak M, Treudler R, Colsman A, et al. Oral graft-versus-host disease: successful therapy with extracorporeal photopheresis and topical tacrolimus. J Eur Acad Dermatol Venereol 2008;22:112-13
60. Albert MH, Becker B, Schuster FR, et al. Oral graft vs. host disease in children - treatment with topical tacrolimus ointment. Pediatr Transplant 2007;11:306-11
61. Fricain JC, Sibaud V, Swetyenga N, et al. Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. Br J Dermatol 2007;156:588-90
62. Conrotto D, Carrozzo M, Ubertalli AV, et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. Transplantation 2006;82:1113-15
63. Eckardt A, Starke O, Stadler M, et al. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 2004;40:811-14
64. Sanchez AR, Sheridan PJ, Rogers RS. Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol 2004;75:613-19
65. Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006;26:66-70
66. Assmann T, Becker J, Ruzicka T, et al. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol 2004;29:674-6
67. Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000;47:436-440
68. Hodgson TA, Malik F, Hegarty AM, et al. Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. Eur J Dermatol 2003;13:142-4
69. Vecchietti G, Kerl K, Hugli A, et al. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. Br J Dermatol 2003;148:833-4
70. Yamamoto T, Nishioka K. Successful treatment with topical tacrolimus for oral psoriasis. J Eur Acad Dermatol Venereol 2006;20:1137-8
71. Corrocher G, Di Lorenzo G, Mansueto P, et al. Comparison of topical tacrolimus 0.1% in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: a 4-week, randomized, double-blind clinical trial. Clin Ther 2006;28:1296-302
72. Werchniak AE, Storm CA, Plunkett RW, et al. Treatment of pyostomatitis vegetans with topical tacrolimus. J Am Acad Dermatol 2005;52:722-3
73. Scully C, Eisen D, Carrozzo M. Management of oral lichen planus. Am J Clin Dermatol 2000;1:287-306
74. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 2007;49:89-106
75. Lopez-Jornet P, Camacho-Alonso F, Salazar-Sanchez N. Topical tacrolimus and pimecrolimus in the treatment of oral lichen planus: an update. J Oral Pathol Med 2007;39:201-5
76. Dissemond J, Schroter S, Franckson T, et al. Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. Br J Dermatol 2004;150:782-4
77. Volz T, Caroli U, Ludtke H, et al. Pimecrolimus cream 1% in erosive oral lichen planus - a prospective randomized double-blind vehicle-controlled study. Br J Dermatol 2008;159:936-41
78. Gorouhi F, Solhpour A, Beitollahi JM, et al. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol 2007;57:806-13
79. Erkek E, Sahin S, Kilic R, et al. A case of cheilitis glandularis superimposed on oral lichen planus: successful palliative treatment with topical tacrolimus and pimecrolimus. J Eur Acad Dermatol Venereol 2007;21:999-1000
80. Esquivel-Pedraza L, Fernandez-Cuevas L, Ortiz-Pedroza G, et al. Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br J Dermatol 2004;150:771-3
81. Dissemond J. Pimecrolimus in an adhesive ointment is safe and effective in long-term treatment for oral lichen planus. J Eur Acad Dermatol Venereol 2008;22:1009-11
82. Passeron T, Lacour JP, Fontas E, et al. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol 2007;143:472-6
83. Swift JC, Rees TD, Plemons JM, et al. The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J Periodontol 2005;76:627-35
84. Nevile B, Damm D, Allen C, et al., Dermatologic diseases. In: Nevile B, Damm D, Allen C, et al., editors, Oral and maxillofacial pathology. 3rd edition. Saunders Elsevier, St. Louis, Missouri; 2009. p. 783
85. Nevile B, Damm D, Allen C, et al. Allergies and immunologic diseases. In: Nevile B, Damm D, Allen C, et al., editors, Oral and maxillofacial pathology. Saunders Elsevier, St. Louis, Missouri; 2009. p. 333
86. Rankin KV, Jones DL, Redding SW. Oral health in cancer therapy. A Guide for Health Care Professionals. Dental Oncology Education Program; American Cancer Society, Texas Division; Texas Dental Foundation, San Antonio; 2003
87. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993;696:9-19
88. Wera S, Zheng L, Hooghe-Peters EL, et al. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. Endocr Res 1995;21:623-33
89. Kim WU, Cho ML, Kim SI, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol 2000;27:324-31
90. Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the penis. Br J Dermatol 2005;152:183-5
91. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003;149:960-7
92. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-23
93. Zakrzewska JM, Forssell H, Glenny AM. Interventions for the treatment of burning mouth syndrome. Cochrane Database Sys Rev 2005 (1): CD002779